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Abstract Rationale: Selective delta opioid receptor ago-
nists have been shown to produce antidepressant-like be-
havioral effects and increase brain-derived neurotrophic
factor (BDNF) mRNA expression when given acutely, but
the chronic effects of delta agonists have been less well
characterized. Objective: The present study examined the
effects of chronic exposure to the delta agonist (+)BW
373U86 (BW) on antidepressant-like behavior in the forced
swim test and on BDNF mRNA expression in comparison
to chronic treatment with the antidepressants fluoxetine,
desipramine, bupropion, and tranylcypromine. Methods:
Sprague–Dawley rats were treated chronic ally with one
of the above treatments and were tested for antidepressant
effects in the forced swim test, and assayed for BDNF
mRNA expression by in situ hybridization. Results: Acute
administration of 10 mg/kg BW produced a significant
antidepressant-like effect in the forced swim test, while
chronic (8- or 21-day) BW administration did not produce
a significant antidepressant-like effect. When 10 mg/kg
BW was administered for 8 days, it produced a significant
increase in BDNF mRNA expression in the frontal cortex,
while having no effect on BDNF expression when given
for 21 days. Chronic bupropion and desipramine signifi-
cantly decreased BDNF expression in the dentate gyrus of
the hippocampus, while fluoxetine had no effect in any
brain region. Chronic tranylcypromine produced a signif-
icant increase in BDNF expression in the CA1 region of
the hippocampus. Conclusions: Chronic exposure to BW
produces tolerance to most effects, although at differential
rates. In addition, increased BDNF mRNA expression does
not appear to be a common effect of chronic administration
of various antidepressants.
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Introduction
Currently prescribed antidepressants increase the synaptic
concentrations of one or more of the monoamine neu-
rotransmitters. The increase in monoamines occurs shortly
after the drug is given; however, humans do not report a
reduction in depressive symptoms for several weeks. In
addition, many antidepressants produce undesirable side
effects, and are ineffective in certain patients. There is a
need, therefore, to find additional targets for the treatment
of depression.
The delta opioid receptor (DOR) is one potential target
for the development of novel antidepressants. The DOR
agonists (+)BW373U86 and SNC80 have been shown to
produce antidepressant-like effects in the rat forced swim
assay (Broom et al. 2002a), a test that reliably predicts the
ability of a compound to produce antidepressant effects
in humans. SNC80 has also been shown to have anti-
depressant-like and anxiolytic-like properties in rats and
mice (Saitoh et al. 2004). Likewise, DOR knockout mice
show depressive-like and anxiety-like behaviors in sever-
al behavioral tests, indicating that the DOR system is im-
portant for normal emotional behavior in mice (Filliol et al.
2000).
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In addition, the DOR agonist (+)BW373U86 has been
shown to dose-dependently increase brain-derived neuro-
trophic factor (BDNF) mRNA expression in the frontal
cortex, hippocampus, and basolateral amygdala after acute
administration (Torregrossa et al. 2004). The ability of
DOR agonists to increase BDNF mRNA expression may
be important for their antidepressant potential because
many commonly prescribed antidepressants and electro-
convulsive shock (ECS) therapy have been reported to in-
crease BDNF mRNA expression in one or more of these
regions (Nibuya et al. 1995; Russo-Neustadt et al. 1999;
DeFoubert et al. 2004). Increases in neurotrophic factor
expression and increased activity at neurotrophin receptors
has been hypothesized to be important for the clinical ef-
fectiveness of antidepressant drugs (Duman 2004).
A large amount of research has been done on the con-
nection between BDNF and depression based on the ob-
servation that chronic antidepressant treatment increases
BDNF mRNA expression; however, this finding has not
often been repeated. In fact, several studies have suggested
that the antidepressants fluoxetine and desipramine have
no effect on BDNF mRNA expression depending on the
time of sacrifice and the exons examined (Coppell et al.
2003; Dias et al. 2003). Therefore, one aim of the present
study was to determine whether chronic administration
of several antidepressants would increase BDNF or TrkB
mRNA expression.
In addition, the effect of chronic exposure to selective
DOR agonists has not been studied extensively in vivo.
Tolerance develops to the convulsant and analgesic effects
in mice (Comer et al. 1993; Hong et al. 1998) and to the
convulsant effects in rats (Broom et al. 2002b). In addi-
tion, Brandt et al. (2001) found that chronic exposure to
the DOR agonist SNC80 resulted in tolerance to SNC
80's effect on reductions in food-maintained responding
in rhesus monkeys. The effect of chronic DOR agonist
treatment on behavior in the forced swim test and on reg-
ulation of BDNF and TrkB mRNA expression has not
been characterized.
Therefore, there were two primary aims of the present
study. The first aim was to characterize the ability of a
DOR agonist to produce antidepressant-like effects and
increase BDNF mRNA expression after chronic admin-
istration to better understand the potential of these com-
pounds as antidepressants in humans, and secondly, to
determine if chronic treatment with various clinically used
antidepressants can increase BDNF mRNA expression
and produce antidepressant-like effects, in part to directly
compare DOR agonists to known antidepressants using
the methodology of our laboratory, and to clarify the ef-
fects of chronic antidepressants on BDNF expression.
Materials and methods
Animals
Male Sprague–Dawley rats (Harlan Sprague–Dawley, In-
dianapolis, IN) were used for all experiments. They were
delivered weighing 250–300 g and were housed three per
cage with ad libitum access to food and water. Animal
rooms were kept on a 12-h light/dark cycle, with lights on
at 0630 hours and a temperature of 21°C. Experiments
were carried out in accordance with the Declaration of
Helsinki and with the Guide for the Care and Use of
Laboratory Animals as adopted and promulgated by the
National Institutes of Health. The study protocols were
approved by the University of Michigan University Com-




N-diethylbenzamide dihydrochloride) was synthesized by
modifications of published protocols (Bishop and McNutt,
1995) and was dissolved in sterile water. Desipramine, bup-
ropion, tranylcypromine (Sigma, St. Louis, MO, USA),
and fluoxetine (Eli Lilly, Indianapolis, IN) were dissolved
in sterile water.
Experimental treatment
Animals were allowed to acclimate to the research facil-
ity for at least 2 days after delivery for all experiments.
In experiment 1, three groups of rats were injected with
10 mg/kg (+)BW373U86 (BW) or sterile water vehicle
subcutaneously (s.c.) once a day for 1, 8, or 21 days. In
all groups, animals were monitored for convulsions in ob-
servation cages for 20 min after injection on every day of
treatment. The rat was then returned to its home cage. On
the last day of treatment (1st, 8th, or 21st day), groups of
vehicle-treated (n=6) and BW-treated (n=6) rats were test-
ed in a 15-min forced swim test (described below) 1 h after
the last injection. Another set of animals that were injected
with vehicle or BW for 8 or 21 days were sacrificed 3 h
after the last injection (n=5 for 8-day group, n=6 for 21-day
group), and the brains were dissected and frozen in iso-
pentane on dry ice. The brains were then sectioned at a
thickness of 20 μm, and slides were stored at −80°C for
later analysis by in situ hybridization (described below).
Animals were sacrificed 3 h after the last injection of BW
because previous work in our laboratory has shown that
the maximum effect of BW on BDNF mRNA expression
is seen at this time point (Torregrossa et al. unpublished
observations).
Experiment 2 aimed to repeat the findings of previous
studies. Therefore, rats were treated with doses of desip-
ramine and tranylcypromine that were previously reported
to increase BDNF mRNA expression (Nibuya et al. 1995).
Fluoxetine and bupropion were given at doses that were
previously shown to be active in the forced swim test in rats
(Broom et al. 2002b; Torregrossa et al. 2004, respectively).
Rats were divided into five groups that received vehicle
(n=5), 15 mg/kg desipramine (n=4), 15 mg/kg fluoxetine
(n=6), or 30 mg/kg bupropion (n=6) intraperitoneally (i.p.)
32
for 21 days, or 7.5 mg/kg tranylcypromine i.p. for 7 days
followed by 10 mg/kg tranylcypromine for the next 14
days (n=4). Three hours after the last injection on the
21st day, brains were dissected as described in Experiment
1. Another set of rats was given vehicle (n=6), desipramine
(n=5), or tranylcypromine (n=4) for 21 days as just
described. One hour after the last injection on the 21st day,
the rats were tested in the 15-min forced swim test as
described below.
Forced swim test
The forced swim test was conducted as described by
Torregrossa et al. (2004). Briefly, rats were videotaped
from above during a 15-min swim period in a cylindrical
container (46×20 cm height×diameter) filled to 30 cm
with 25°C (±1) water. An observer blind to treatment
scored the videotapes, classifying behaviors every 5 s for
the entire 15-min period. The behaviors observed were
immobility, swimming, and climbing, which were defined
as described by Broom et al. (2002a,b) and Detke et al.
(1997).
In situ hybridization histochemistry
Brain-derived neurotrophic factor and TrkB mRNA levels
were determined by a double-label in situ hybridization
with a [35S]-labeled antisense BDNF or TrkB RNA probe
as described by Torregrossa et al. (2004). The rat TrkB
cDNA (described by Middlemas et al. 1991) was donated
by Dr. Hunter (The Salk Institute). The rat BDNF cDNA
(described by Isackson et al. 1991) was donated by Drs.
Gall and Lauterborn (University of California, Irvine). To
verify that the rat BDNF probe produces little to no
nonspecific binding, control slides were hybridized with
a [35S]-labeled sense strand BDNF cRNA probe, which
was made using the T7 RNA polymerase from linearized
BDNF cDNA. These slides were processed for in situ hy-
bridization in the same manner as slides labeled with the
antisense probe.
The slides were exposed on Kodak XAR film (Eastman
Kodak, Rochester, NY), and films were developed after
14 days for BDNF and 3 days for TrkB.
Quantification of radioactive signal
Brain-derived neurotrophic factor and TrkB mRNA levels
were quantified using NIH Image (Scion Image Corp.,
Frederick, MD) software. BDNF mRNA expression after
BW administration was examined in the frontal cortex; the
CA1, the CA3, and the dentate gyrus regions of the hip-
pocampus; the basolateral amygdaloid complex; the en-
dopiriform nucleus; primary olfactory cortex; and the
postcingulate cortex. All of these regions, with the ex-
ception of the dentate gyrus and postcingulate cortex, have
increased BDNF mRNA expression after acute BW ad-
ministration. BDNF mRNA expression for the antidepres-
sant-treated groups and TrkB mRNA expression for all
groups was examined in the frontal cortex and the CA1,
CA3, and dentate gyrus regions of the hippocampus. Each
brain region was analyzed by creating an outline around
the region and measuring both the left and right sides of
the brain from rostral–caudal sections 100–200 μm apart.
At least six sections per region per rat were quantified.
The signal measurements were corrected for background
and were determined as the mean radioactive intensity per
pixel for that region. These signal values for each section
were then averaged to obtain the mean signal for each
region in each rat. These data points were then averaged
per group and compared statistically.
Statistical analysis
All comparisons between multiple groups were conducted
by one-way ANOVA. Tukey’s post hoc test was used to
determine differences between groups where p<0.05 was
considered significant.
Results
Effects of chronic exposure to a delta agonist
Rats received injections of 10 mg/kg BW or vehicle every
day for 21 days. These animals were weighed every day
and monitored for convulsions and any overt signs of
physical dependence (i.e., withdrawal), but withdrawal
signs were not quantified. Figure 1a illustrates the aver-
age weight of each group of animals over the course of
the 21 days of treatment. There was no difference in
weight between the vehicle- and BW-treated groups on
any day of treatment. In contrast, animals receiving de-
sipramine, fluoxetine, and tranylcypromine for 21 days all
lost weight after the initial days of treatment, and the av-
erage weights of all three groups were significantly dif-
ferent from vehicle-treated rats beginning on day 6 and on
every subsequent day of treatment (Fig. 1b). Rats receiving
bupropion initially lost a very small amount of weight
but did not significantly differ from vehicle on any day
but day 2.
In addition, the rats receiving BW showed no outward
signs of physical dependence or withdrawal on a day-to-
day basis. However, rats receiving desipramine, fluoxe-
tine, and tranylcypromine often had diarrhea and were
aggressive toward the experimenter and other rats in its
home cage.
Finally, on the first day of BW administration, five of
six rats had a clonic convulsion within 20 min of injec-
tion (data not shown). On every subsequent day of BW




A single injection of 10 mg/kg BW given 1 h prior to a
15-min forced swim test produced a significant reduction
in immobility, with concomitant significant increases in
both swimming and climbing (Fig. 2a). The reduction in
immobility suggests an antidepressant-like effect of BW,
which has been previously reported (Broom et al. 2002a,b).
Conversely, when 10 mg/kg BW is administered for 8 or
21 days before the forced swim test; there is no longer
any significant reduction in immobility when compared
to controls (Fig. 2b,c).
In contrast, the antidepressants desipramine and tranyl-
cypromine both produced significant reductions in immo-
bility in the forced swim test after 21 days of administration
(Fig. 3). Desipramine also produced a significant increase
in climbing, while tranylcypromine produced significant
increases in both swimming and climbing.
Regulation of BDNF and TrkB mRNA expression
Brain-derived neurotrophic factor mRNA expression was
measured in animals that had been treated with 10 mg/kg
BW for 8 and 21 days. After 8 days of BW administra-
tion, BDNF mRNA expression was significantly increased
in the frontal cortex (Fig. 4). There were no significant
changes in BDNF mRNA expression in any other brain
region after 8 days of BW. In addition, 21 days of BW
administration had no effect on BDNF mRNA expression
in any brain region (data not shown). Finally, neither 8- nor
21-day exposure to BW had any effect on TrkB mRNA
expression in any brain region examined (data not shown).
Several antidepressants have been reported to regulate
BDNF and TrkB mRNA expression particularly in the
hippocampus (Nibuya et al. 1995). Therefore, we exam-
ined the effect of chronic (21-day) exposure to the anti-
Fig. 1 The body weight
of rats receiving a chronic
10 mg/kg (+)BW373U86 (BW)
or b chronic antidepressant
treatment. The weight in grams
of each rat was recorded every
day prior to injection of test
compound and is expressed as
the group mean on each day±
SEM. The weight of BW-treated
rats did not significantly differ
from vehicle-treated rats. DMI,
FLX, and TCP all significantly
reduced body weight compared
to vehicle controls on days
6–21
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depressants desipramine, bupropion, fluoxetine, and tra-
nylcypromine on BDNF and TrkB mRNA expression in
the frontal cortex, and the CA1, CA3, and dentate gyrus
regions of the hippocampus. None of the compounds pro-
duced a significant change in BDNF expression in the
frontal cortex. Both desipramine and bupropion signifi-
cantly decreased BDNF mRNA expression in the den-
tate gyrus, while having no effect in the other regions
of the hippocampus. Fluoxetine had no effect on BDNF
mRNA expression in any brain region examined. On the
other hand, tranylcypromine significantly increased BDNF
mRNA expression in the CA1 region of the hippocampus
and tended to increase expression in the CA3 and dentate
gyrus regions, although not significantly (Fig. 5). Finally,
none of the antidepressants tested had any effect on TrkB
mRNA expression in the frontal cortex or hippocampus
(data not shown).
Discussion
The delta opioid receptor agonist BW has been shown
to produce convulsions, antidepressant-like effects, and
regulates BDNF mRNA expression upon acute admin-
istration (Comer et al. 1993; Broom et al. 2002a,b;
Torregrossa et al. 2004). However, few studies have exam-
ined the behavioral or neurobiological effects of chronic
exposure to selective delta agonists. The present study ex-
amined the effects of chronic delta agonist administration
on weight, convulsions, antidepressant-like effects, and
BDNF mRNA expression. In addition, this study compared
the effects of BW to several antidepressant drugs.
Chronic exposure to 10 mg/kg BW did not affect weight
or amount of weight gain in rats when compared to con-
trols unlike mu opioid receptor agonists, which may cause
weight loss in rats under chronic exposure conditions (Azar
et al. 2004). In addition, chronic BW treatment did not
result in any other obvious behavioral signs of physical
dependence (withdrawal occurrence between doses). Chron-
ic treatment with fluoxetine, desipramine, and tranylcy-
promine, but not bupropion, resulted in initial weight loss
and either continued weight loss or minimal weight gain
Fig. 3 Effects of chronic DMI and chronic TCP on behavior in the
forced swim test. Chronic (21-day) treatment with 15 mg/kg DMI
significantly reduces immobility (p<0.05) and significantly in-
creases climbing (p<0.01) in the forced swim test. TCP, given at a
dose of 7.5 mg/kg for 7 days and 10 mg/kg for the following 14
days, significantly reduces immobility (p<0.01), and significantly
increases swimming (p<0.05) and climbing (p<0.05) in the forced
swim test. * indicates p<0.05 and **, p<0.01
Fig. 2 Effect of acute and chronic 10 mg/kg BW on behavior in the
forced swim test. a An acute injection of 10 mg/kg BW significantly
reduces immobility (p<0.001) and significantly increases swimming
(p<0.001) and climbing (p<0.05) in the forced swim test, indicating
an antidepressant like effect. b 10 mg/kg BW given for 8 days has
no significant effect on behavior in the forced swim test. c 10 mg/kg
BW given for 21 days also has no significant effect on behavior in
the forced swim test. * indicates p<0.05 and ***, p<0.001
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when compared to controls. In addition, these animals
were often very irritable and aggressive.
A single administration of 10 mg/kg BW produces a
clonic convulsion in most animals and produces a signif-
icant antidepressant-like effect in the forced swim test.
When 10 mg/kg BW is given on two consecutive days,
none of the animals will have a convulsion on the second
day; however, the antidepressant-like effect is maintained
(Broom et al. 2002b). In the present study, 10 mg/kg BW
was given for 8 and 21 days. None of the animals had a
convulsion on any day save for the first day of treatment.
BW administered for 8 and 21 days did not produce a
significant antidepressant-like effect in the forced swim
test, indicating that tolerance does eventually develop to
the antidepressant-like effects of BW. In contrast, the anti-
depressants desipramine and tranylcypromine produced
antidepressant effects in the forced swim test after a 21-
day administration, indicating that tolerance does not de-
velop to the behavioral effects of these antidepressants
under these conditions.
In addition, we have previously shown that 10 mg/kg
BW increases BDNF mRNA expression in several brain
regions, including the frontal cortex, when given acutely,
and increases BDNF mRNA expression in the frontal cor-
tex when given on two consecutive days (Torregrossa et al.
2004). In this study, we found that 8 days of treatment
with 10 mg/kg BW continued to produce a significant in-
crease in BDNF mRNA expression in the frontal cortex,
whereas at 21 days of treatment, this effect disappeared.
BDNF mRNA expression is increased throughout the fron-
tal cortex, suggesting a possible nonspecific effect; how-
ever, delta receptors are expressed throughout the frontal
cortex (Mansour et al. 1993), so it is possible that the
increase in BDNF mRNA expression is directly regulated
by delta opioid receptor activation. Delta opioid receptors
can activate the mitogen-activated protein kinase (MAPK)
Fig. 4 Brain-derived neuro-
trophic factor mRNA expression
after 8 days of treatment with
vehicle or 10 mg/kg BW.
a–d Photomicrographs from
x-ray films exposed for 14 days
after in situ hybridization with
the antisense cRNA probe to rat
BDNF mRNA. Photos show
sections through the frontal
cortex and at the level of the
hippocampus. a, c Sections from
a vehicle-treated animal.
b, d Sections from an animal
treated with 10 mg/kg BW for 8
days. e Quantification of BDNF
mRNA signal in frontal cortex,
CA1, CA3, and dentate gyrus
of hippocampus, basolateral
amygdala (BLA), endopiriform
nucleus (EN), olfactory cortex
(Olf Ctx), and postcingulate
cortex (PCg Ctx), expressed
as mean±SEM. *** indicates
p<0.001
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pathway (Kramer et al. 2002; Persson et al. 2003), and
activation of the MAPK pathway can lead to up-regulation
of BDNF mRNA expression (Wu et al. 2004), providing a
potential mechanism of delta-induced increases in BDNF
mRNA expression.
It is unclear why tolerance develops to increases in
BDNF mRNA expression in all brain regions other than
the frontal cortex after a single administration. The largest
effect of BW on BDNF expression is seen in the frontal
cortex, so while there is some tolerance after a single in-
jection, a significant increase can still be seen with multi-
ple days of injections, whereas in the brain regions where
there are acutely smaller increases in BDNF, all effect is
lost with the “partial” tolerance that develops from the first
injection. However, it may also be the case that delta re-
ceptors regulate BDNF expression differentially depending
on the brain region.
Alternatively, the apparent tolerance that develops to
increases in BDNF mRNA expression over time can be
explained by feedback regulation of the system. The pre-
sumed constant increase in BDNF expression caused by
over 8 days of BW treatment should lead to an increase
in BDNF protein, which could, in turn, negatively feed-
back to reduce BDNF mRNA expression. While this is
a possibility that should certainly be tested, a study by
Saarelainen et al. (2001) suggests that BDNF actually feeds
back to positively alter its expression. In their study, trans-
genic mice were developed that express the dominant neg-
ative form of the TrkB receptor, which results in a
reduction in BDNF signaling. It was found that kainic
Fig. 5 Brain-derived neurotro-
phic factor mRNA expression
after chronic antidepressant
treatment. a–e Photomicro-
graphs from x-ray films exposed
for 14 days after in situ hybrid-
ization with the antisense cRNA
probe to rat BDNF mRNA.
Photos show sections through
the hippocampus. a Section
of 21-day vehicle treatment.
b Section from chronic TCP
treatment c Section from chronic
bupropion treatment. d Section
from chronic DMI treatment.
e Section from chronic fluoxe-
tine treatment. f Photomicro-
graph from a section through
the hippocampus after in situ
hybridization with the sense
cRNA probe to rat BDNF
mRNA, illustrating that there
is no nonspecific binding.
g Quantification of BDNF
mRNA signal in frontal cortex,
CA1, CA3, and dentate gyrus
of hippocampus expressed as
percent of vehicle control.
* indicates p<0.05 and **,
p<0.01
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acid induced up-regulation of BDNF mRNA was great-
ly reduced in the transgenic mice compared to wild types,
implying that BDNF signaling through TrkB is nec-
essary to produce a maximal increase in BDNF mRNA
expression.
Therefore, it is most likely that the lack of BDNF ex-
pression seen after 21 days of BW is due to tolerance
development, but the time course of tolerance development
differs depending on the end point studied. This can be
explained by differences in the receptor reserve required
to produce each effect. There may be a greater receptor
reserve available for the production of antidepressant-like
behavioral effects than for producing convulsions, and an
even greater reserve available for producing increases in
BDNF mRNA expression in the frontal cortex. In support
of this hypothesis, we previously found that a dose of
1 mg/kg BW significantly increased BDNF mRNA ex-
pression in the frontal cortex, while this dose is insufficient
to produce convulsions, antinociception, or antidepres-
sant-like effects (Torregrossa et al. 2004; Broom et al.
2002a).
Increases in the expression of growth factors and their
receptors, particularly BDNF and its high-affinity tyrosine
kinase receptor, TrkB, has been hypothesized to be im-
portant for the therapeutic effects of antidepressant drugs.
Chronic administration of several antidepressant drugs and
ECS was reported to increase the expression of BDNF in
the hippocampus (Nibuya et al. 1995). Moreover, BDNF
injected directly into the midbrain or hippocampal CA3
or dentate gyrus regions has been shown to produce anti-
depressant-like effects in the forced swim test (Siuciak
et al. 1997; Shirayama et al. 2002). Therefore, a treatment
that increases activity of the BDNF/TrkB system acutely
may reverse the symptoms of depression more rapidly
than current therapies. A fast-acting antidepressant is ben-
eficial for reducing hospitalization times for the severely
depressed and to potentially help suicidal patients more
rapidly than current antidepressants. The selective non-
peptidic delta opioid receptor agonists, like BW, may be
fast-acting antidepressants because of their ability to acute-
ly up-regulate BDNF mRNA expression. Long-term treat-
ment with delta agonists is likely to result in tolerance
development to some of the effects, but BDNF expression
may continue to be increased for at least 1 week of
administration, and this may provide sufficient stimulus
for rapid recovery from a depressive episode. Therefore,
DOR agonists are potentially very important compounds
to develop for the acute treatment of a depressive episode.
If chronic therapy becomes necessary to maintain proper
mental health, then the dose may need to be escalated, or
the compound may need to be taken once every few days
to allow the tolerance to reverse between administrations.
However, the development of DOR agonists for human
use will require finding a compound that can produce
antidepressant-like effects at much lower doses than it
produces convulsions. Work in our laboratory has shown
that slowing the entry of DOR agonists into the brain by
either slow intravenous infusion or oral administration can
enhance the separation between doses that produce anti-
depressant-like effects without a convulsion and those that
produce convulsions (Jutkiewicz et al. 2005). Therefore, it
should be possible to develop DOR agonists that can be
administered in a way to produce antidepressant-like
effects and increases in BDNF mRNA expression without
producing convulsions.
Increased expression of BDNF and/or TrkB expression,
however, may not be required for the therapeutic actions
of currently used antidepressants. The present study at-
tempted to clarify the confusion in literature by examining
whether 21 days of treatment with the antidepressants de-
sipramine, fluoxetine, bupropion, and tranylcypromine
can indeed regulate BDNF or TrkB mRNA expression.
We found that only tranylcypromine significantly in-
creased BDNF expression in the hippocampus. In fact,
both desipramine and bupropion significantly decreased
BDNF mRNA expression in the dentate gyrus of the hip-
pocampus, while fluoxetine had no effect. In addition, none
of the antidepressants had any effect on TrkB mRNA ex-
pression in the frontal cortex or hippocampus. Therefore,
increased expression of BDNF and/or TrkB does not ap-
pear to be a common effect of chronic treatment with var-
ious antidepressants.
Several other laboratories have reported no significant
increases in BDNF expression after chronic antidepressant
treatment. Miro et al. (2002) found that 14 days of 3 mg/kg
intraperitoneal fluoxetine significantly decreased BDNF
mRNA expression in several regions, including the CA
and dentate gyrus regions of the hippocampus. Coppell
et al. (2003) found that fluoxetine significantly reduced
BDNF expression in the hippocampus when animals were
sacrificed 4 h after the last injection but significantly
increased BDNF expression in the hippocampus when
animals were sacrificed 24 h after the last injection,
suggesting that fluoxetine induced increases in BDNF
mRNA expression may only be seen 24 h after the last
treatment.
While Nibuya et al. (1995) found that 21 days of de-
sipramine increased BDNF mRNA expression in the hip-
pocampus when animals were sacrificed 3 h after the last
treatment, we found the opposite effect. Coppell et al. (2003)
found that 2 weeks of desipramine had no effect on BDNF
expression when the animals were sacrificed 24 h after
injection. In contrast, Jacobsen and Mork (2004) found that
21 days of 10 mg/kg desipramine did moderately, but sig-
nificantly, increase BDNF expression in the dentate gyrus.
Therefore, the literature regarding the effects of desipra-
mine on BDNF expression is quite variable, and the dif-
ferences may be due to differences in dosing regimens,
time of sacrifice, and/or in the methods used to quantify
mRNA levels.
The effect of tranylcypromine on BDNF expression
appears more consistent, and concurs with our finding in
the present study that tranylcypromine significantly in-
creases BDNF expression in the hippocampus (Nibuya
et al. 1995; Russo-Neustadt et al. 1999). The present study
is the first to examine the effects of bupropion, a pref-
erential dopamine reuptake inhibitor, on BDNF mRNA
expression. We found that chronic bupropion significantly
38
decreased BDNF expression in the dentate gyrus and had
no effect in any other brain region. While chronic bup-
ropion has not been studied previously. Nibuya et al.
(1995) did examine the effects of chronic 15 mg/kg cocaine
i.p. on BDNF expression. Due to the similar mechanism of
action of cocaine and bupropion, one might expect to see
similar effects on gene expression. In fact, Nibuya et al.
(1995) found no significant effect of chronic cocaine on
BDNF expression in any brain region.
In conclusion, while acute administration of the selective
delta opioid receptor agonist BW consistently produces
behavioral antidepressant-like effects and increases BDNF
mRNA expression in the frontal cortex, tolerance does
eventually develop to these effects after chronic treatment.
However, chronic treatment with the antidepressants flu-
oxetine, desipramine, and bupropion did not produce a
significant increase in BDNF mRNA expression in any
brain region, indicating that an increase in BDNF gene
expression after chronic treatment is not a common effect
of all antidepressants, and may not be necessary for the
clinical effectiveness of these drugs. Alternatively, treat-
ments like ECS and tranylcypromine that show increases in
BDNF expression may be more effective in treating de-
pression. Therefore, the rapid increase in BDNF expression
produced by delta opioid receptor agonists may indicate
that these drugs can provide an alternative antidepressant
treatment for treatment resistant depression or in cases
where a more rapid clinical response is desired.
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